119 232

Cited 11 times in

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients

Authors
 Seung-Hoon Beom  ;  Dong-Wan Kim  ;  Sung Hoon Sim  ;  Bhumsuk Keam  ;  Jin Hyun Park  ;  Jeong-Ok Lee  ;  Tae Min Kim  ;  Se-Hoon Lee  ;  Dae Seog Heo 
Citation
 CANCER RESEARCH AND TREATMENT, Vol.48(1) : 88-97, 2016 
Journal Title
CANCER RESEARCH AND TREATMENT
ISSN
 1598-2998 
Issue Date
2016
MeSH
Antineoplastic Agents/adverse effects* ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy* ; Humans ; Lung Diseases, Interstitial/chemically induced* ; Lung Neoplasms/drug therapy* ; Quinazolines/adverse effects* ; Quinazolines/therapeutic use ; Retrospective Studies ; Seoul
Keywords
Drug-related side effects and adverse reactions ; Gefitinib ; Interstitial lung diseases ; Lung injury ; Lung neoplasms
Abstract
PURPOSE: Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the incidence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carcinoma patients treated with gefitinib.

MATERIALS AND METHODS: A retrospective cohort study was performed in non-small cell lung cancer (NSCLC) patients who started gefitinib treatment at Seoul National University Hospital from January 2002 through December 2011. Patients who developed new abnormal radiologic findings with respiratory symptoms after gefitinib treatment were defined as having possible adverse pulmonary reactions. The patients' medical records were reviewed independently by investigators to identify the causes of pulmonary toxicities.

RESULTS: Among the 1,114 patients evaluated, 128 patients (11.5%) developed pulmonary adverse reactions after taking gefitinib. An infectious complication occurred in 98 patients (8.8%) and 15 patients (1.3%) developed ILD. Nine of the 15 patients (60.0%) with gefitinib-induced ILD experienced a fatal clinical course that met either the Common Terminology Criteria for Adverse Events grade 4 (n=3) or grade 5 (n=6). In the multivariate analysis, a lower serum albumin level (≤ 3.0 g/dL) at baseline was significantly associated with the development of gefitinib-induced ILD (odds ratio, 3.91; 95% confidence interval, 1.20 to 12.71).

CONCLUSION: The incidence of gefitinib-induced ILD in Korean NSCLC patients was similar to that reported worldwide, but lower than values reported for Japanese population. ILD was usually a life-threatening adverse effect of gefitinib, and the development of ILD was significantly associated with a lower baseline serum albumin level.
Files in This Item:
T201606299.pdf Download
DOI
10.4143/crt.2014.201
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Beom, Seung Hoon(범승훈) ORCID logo https://orcid.org/0000-0001-7036-3753
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/153124
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links